Keyphrases
Antiproliferative Activity
20%
Aurora Kinase A (AURKA)
20%
CCNB1
20%
Cell Cycle Arrest
20%
Cell Proliferation
20%
Chemotherapy
40%
Cyclin-dependent Kinase 4 (CDK4)
20%
Differentially Expressed
20%
DNA Damage Repair
20%
Drug Mechanism of Action
20%
Dual HER2 Blockade
20%
Endocrine Therapy
20%
ER +
100%
ER Signaling
20%
Gene Analysis
20%
HER2+ Breast Cancer
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
40%
Hypertension
20%
Ki-67
60%
Letrozole
100%
Leukopenia
20%
Luminal B
20%
MKI67
20%
Molecular Signature
20%
MTORC1 Signaling
20%
Neoadjuvant
40%
Neoadjuvant Therapy
100%
Neutropenia
20%
Palbociclib
100%
PAM50
40%
Pathological Complete Response
80%
Patient Accrual
20%
Phase II Study
100%
Polo-like Kinase 1 (PLK1)
20%
Research Biopsy
20%
Residual Cancer
20%
RNA Sequencing (RNA-seq)
40%
Signature Database
20%
Trastuzumab
100%
Treatment-related Adverse Events
20%
Whole Exome Sequencing
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
20%
Chemotherapy
40%
Drug Action
20%
Endocrine Therapy
20%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Letrozole
100%
Leukopenia
20%
Malignant Neoplasm
20%
Neutropenia
20%
Palbociclib
100%
RNA-Sequencing
40%
Trastuzumab
100%
Biochemistry, Genetics and Molecular Biology
Antiproliferative Activity
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Proliferation
20%
DNA Repair
20%
Drug Mechanism
20%
Exome Sequencing
20%
Letrozole
100%
PLK1
20%
RNA Sequence
40%
Subtyping
40%
Trastuzumab
100%
Immunology and Microbiology
Antiproliferative Activity
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Proliferation
20%
DNA Repair
20%
Drug Mechanism
20%
RNA Sequence
40%
Trastuzumab
100%
Whole Exome Sequencing
20%